Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Elisabetta ZulatoPaola Del BiancoGiorgia NardoIlaria AttiliAlberto PavanAndrea Boscolo BragadinLudovica MarraGiulia PaselloMatteo FassanFiorella CalabreseValentina GuarneriPier Franco ConteStefano IndraccoloLaura BonannoPublished in: British journal of cancer (2022)
Liquid biopsy performed early during treatment has the potential to identify patients at high risk of ED and HPD.